Even among cancers, pancreatic cancer is an especially sinister form of disease. The one-year survival rate is extremely low, and treatment progress has lagged behind that of many other malignancies.
A study published today in the journal Nature Medicine led by researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) describes a new therapeutic approach with potential for patients with pancreatic cancer. These researchers discovered a combination drug therapy that may effectively combat the disease. HCI researchers first observed anti-cancer impacts in a laboratory setting and, subsequently, in its first use in a human patient.
The study has already progressed to a clinical trial that is now open at HCI and will soon be open at other sites in the United States. Details about the clinical trial, called THREAD, are available under National Clinical Trial Number 03825289. The combination therapy uses two drugs already approved for use by the Food and Drug Administration for other diseases, including cancer. The new drug combination is administered through pills taken orally.
Pancreatic tumors are characterized by mutations in a gene called KRAS. When KRAS is mutated in this way, it sends constant signals that promote abnormal cell division and growth in cancer cells. As a result, tumors grow out of control. At the same time, like all cells, pancreatic cancer cells must recycle their components to provide building blocks for new growth in an essential cell function known as autophagy. Previous studies to combat pancreatic cancer that were focused either on the role of KRAS or on impacting autophagy were not effective.
The new HCI study, using an approach that simultaneously targets both abnormal KRAS signaling and the autophagy process, shows a strong response in mouse models and may be a promising therapy for patients with pancreatic cancer. Conan Kinsey, MD, PhD, a physician-scientist at Huntsman Cancer Institute and the Department of Internal Medicine at the U of U and Martin McMahon, PhD, a cancer researcher at HCI and Professor of Dermatology at the U of U, led the study.
“We were able to observe that the combination of these two drugs – which, when used individually, don’t have much of an impact on the disease – appears to have a very potent impact on the growth of pancreatic cancer,” says McMahon. “We have observed this in the lab in petri dishes, then in mouse models, and now in a pancreatic cancer patient on a compassionate use basis. Indeed, we proceeded from a petri dish to a patient in less than two years – a timeline that is rarely seen in medical science.”
The HCI-led research is bolstered by a separate study published in the same issue of the journal. This study outlines complementary findings regarding the effects of autophagy in pancreatic cancer in the laboratory setting and was led by Channing Der, PhD, Sarah Graham Kenan, PhD, and Kirsten Bryant, PhD, at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center. McMahon and Der learned about the parallel nature of their research programs at a scientific meeting one year ago. Given the critical need for advances in pancreatic cancer therapies and the promise of their collective findings, they worked together to push their studies forward on a companion basis.
“In our paper, we show the response of a pancreatic cancer patient who had received surgery and multiple lines of chemotherapy prior to this combination,” said Kinsey, who was also the patient’s physician. “This patient, who has since succumbed to the disease, nevertheless had a remarkable response to these drugs for several months. We need to carefully evaluate this new combination therapy in the context of clinical trials to better understand if good responses might be seen in multiple patients. We also need to identify the specific features of any patient who may benefit, before any recommendation can be made about use on a larger scale.”
These preliminary findings are being rigorously scrutinized in clinical trials to observe and understand whether the combination of these drugs is safe and effective for pancreatic cancer patients. The trial is underway at HCI and is underway or planned at the University of California, San Francisco, and Columbia University in New York.
“In publishing how this new approach of mixing two medicines typically associated with malaria and melanoma can treat pancreatic tumors with KRAS mutations, we are hoping the clinical trial supported by the Pancreatic Cancer Collective’s New Therapies Challenge Grant will help us learn how to best administer these medicines, so that we can maximize the benefit for as many patients as possible,” said David Tuveson, MD, PhD, Lustgarten’s Chief Scientist, Director of the Cancer Center at Cold Spring Harbor Laboratory, Co-Scientific Leader of the Collective.
Learn more: Promising New Pancreatic Cancer Treatment Moves Forward
The Latest on: Pancreatic cancer
[google_news title=”” keyword=”pancreatic cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pancreatic cancer
- Contract negotiations continue for Troy teacherson May 2, 2024 at 7:31 am
Continued contract negotiations between the Troy School District and their teachers has left some questioning the district’s support of its educators and others pointing to what they called systemic ...
- Pancreatic Cancer Cells Differ by Location and May Inform Targeted Treatmentson May 2, 2024 at 2:09 am
A new study has found that pancreatic cancer cells are different based on their location in the pancreas, providing new information about tumors that could lead to better targeted treatments.
- Hartford HealthCare awarded grant for pancreatic cancer researchon May 1, 2024 at 10:10 am
In an important effort to fight pancreatic cancer, Hartford HealthCare has been awarded a special grant by the Ron Foley Foundation.
- HealthWatch: Early Pancreatic Cancer Detection Gives Patients an Advantageon May 1, 2024 at 7:59 am
Pancreatic cancer is on the rise, especially in people younger than 55. It’s also increasing more rapidly in women than in men. More than 56 thousand ...
- Researchers find difference in pancreatic cancer cells, offering new hope for immunotherapy effectivenesson May 1, 2024 at 6:32 am
A new study has found that pancreatic cancer cells are different based on their location in the pancreas, providing new information about tumors that could lead to better targeted treatments.
- Study highlights differences in pancreatic cancer cells based on locationon April 30, 2024 at 9:47 pm
A new study has found that pancreatic cancer cells are different based on their location in the pancreas, providing new information about tumors that could lead to better targeted treatments.
- PurpleStride Pittsburgh charity walk raises money for pancreatic cancer researchon April 27, 2024 at 5:01 pm
The Pancreatic Cancer Action Network held Purple Stride Pittsburgh, where survivors, families, caregivers, researchers and supporters raise money through the walk. KDKA-TV's Kristine Sorensen served ...
- “Star Trek ”Actress Kitty Swink Had a 4% Survival Rate After Pancreatic Cancer — It's Been 20 Years (Exclusive)on April 25, 2024 at 8:44 am
"Seventeen days later, I came out of Cedars-Sinai with half my stomach, half my pancreas, my gallbladder gone, two feet of my intestines removed out, 28 lymph nodes removed and a 4% chance of ...
- Scottsdale pancreatic cancer survivor under the influence of hopeon April 23, 2024 at 12:10 am
The 55-year-old from Scottsdale had to undergo months of radiation, chemotherapy, then surgery. Now, he’s under the influence of hope. It wasn’t his first instinct. “I changed my mind this year,” ...
- What Is Pancreatic Cancer?on April 22, 2024 at 5:30 am
Pancreatic cancer develops when abnormal cells in the pancreas grow uncontrollably, causing symptoms like fatigue, jaundice, and urinary changes.
via Bing News